<DOC>
	<DOCNO>NCT02870699</DOCNO>
	<brief_summary>Docetaxel widely use oncology treatment many solid tumor . The side effect docetaxel many sometimes serious . The primary toxicity docetaxel neutropenia . Skin nail manifestation , frequency , second category adverse event haematological adverse event . Use product Evonail® demonstrate patient treat doxetaxel nail damage . The purpose study confirm effectiveness film-forming solution Evonail® versus placebo prevention nail damage woman breast cancer treat adjuvant docetaxel .</brief_summary>
	<brief_title>Efficacy Evonail® Solution Prevention Nail Damage Induced Docetaxel Patients With Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Age ≥ 18 year old Patient breast carcinoma Patients treat adjuvant chemotherapy ( FEC + 3 docetaxel +/ Herceptin® ) Patients never treat taxanes Patients nail damage start study ECOG performance &lt; 2 Ability provide write informed consent Patient allergic treatment component Use filmforming solution , solvent product apply fingernail ( artificial nail ... ) three week first docetaxel treatment Risk exposure aggressive factor nail study Using refrigerant glove chemotherapy treatment Onychophagia Presence nail disease history nail pathology ( infectious ) Pregnant breast feeding female Patients whose condition compatible followup study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>chemotherapy neoadjuvant</keyword>
</DOC>